Abstract
Variant hemoglobin is often detected during the diagnosis and treatment of diabetes mellitus. We here describe a case of α2-chain variant hemoglobin (Hb Chad) that was identified as a result of differences in HbA1cs values determined by different assays. HbA1c measured by immunoassay was thus falsely high, whereas that measured by high-performance liquid chromatography (HPLC) was slightly low. Sequencing analysis revealed a heterozygous GAG (glutamic acid) → AAG (lysine) mutation at amino acid position 23 of the α2-globin gene. This residue is located at the surface of the α-chain in the crystal structure of hemoglobin. The high HbA1c value determined by immunoassay might have been the result of increased antigenicity of the variant hemoglobin, whereas the low value measured by HPLC reflected differential fractionation of the variant relative to the wild-type protein. Hb Chad has been reported in only three cases to date, and HbA1c was measured for the first time. This is the first case where falsely high HbA1c measured by immunoassay due to increased antigenicity in α-chain variant hemoglobin. This case highlights the importance of comparison with other parameters related to plasma glucose such as glycated albumin if an HbA1c abnormality is suspected.
This is a preview of subscription content, log in via an institution to check access.
References
American Diabetes Association. Glycemic targets: standards of medical care in diabetes-2019. Diabetes Care. 2019;42(suppl 1):S61–70.
Koga M. Glycated albumin; clinical usefulness. Clin Chim Acta. 2014;433:96–104.
Bry L, Chen PC, Sacks DB. Effects of hemoglobin variants and chemically modified derivatives on assays for glycohemoglobin. Clin Chem. 2001;47:153–63.
Miyazaki A, Kohzuma T, Kasayama S, Koga M. Classification of variant forms of haemoglobin according to the ratio of glycated haemoglobin to glycated albumin. Ann Clin Biochem. 2012;49:441–4.
Wajcman H. Human Hemoglobin Variants, the Electric Versions, http://globin.cse.psu.edu. Accessed 24 Dec 2019.
Schnedl WJ, Krause R, Halwachs-Baumann G, Trinker M, Lipp RW, Krejs GJ. Evaluation of HbA1c determination methods in patients with hemoglobinopathies. Diabetes Care. 2000;23:339–44.
Thomas LB, Agosti SJ, Man MA, Mastorides SM. Screening for hemoglobinopathies during routine hemoglobin A1c testing using the Tosoh G7 Glycohemoglobin Analyzer. Ann Clin Lab Sci. 2007;37:251–5.
Boyer SH, Crosby EF, Fuller GF, et al. A survey of hemoglobins in the Republic of Chad and characterization of hemoglobin Chad: alpha-2-23Glu→Lys-beta-2. Am J Hum Genet. 1968;20:570–8.
Tahara Y, Shima K. Evaluation of error levels in hemoglobin A1c and glycated albumin in type 2 diabetic patients due to inter-individual variability. Diabetes Res Clin Pract. 2010;89:115–20.
Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine RJ, A1c-Derived Average Glucose Study Group. Translating the A1C assay into estimated average glucose values. Diabetes Care. 2008;31:1473–8.
Blackwell RQ, Weng MI, Huang JT. Haemoglobin Chad, alpha23 GLU leads to LYS, in a Chinese family in Taiwan. Trop Geogr Med. 1973;25:393–6.
Harano T, Harano K, Shibata S, et al. Hemoglobin Chad [alpha 23 (B4) Glu replaced by Lys] discovered in a Japanese with questionable polycythemia. Hemoglobin. 1983;7:581–4.
Furuya M, Koga M, Ishibashi M, Toyoda M, Tsujii S. A Case of Variant Hemoglobin HbC in a Non-Diabetic Subject Treated with Anti-Diabetic Drugs Due to Falsely High HbA1c Levels Measured By an Immunoassay. J Japan Diab Soc. 2016;59:463–8.
Yamane Y, Tsumori M, Ishibashi M, Koga M. A case of variant hemoglobin (Hb Agenogi) with type 2 diabetes mellitus showed high HbA1c levels measured by immunoassay due to enhanced antigenicity. Diabetol Int. 2019;10:138–42.
Ohba Y, Miyaji T, Murakami M, et al. Hb Himeji or beta 140 (H18) Ala→Asp. A slightly unstable hemoglobin with increased beta N-terminal glycation. Hemoglobin. 1986; 10: 109–125.
Forget BG. Molecular genetics of human hemoglobin synthesis. Ann Intern Med. 1979;91:605–16.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no conflicts of interest.
Human and animal rights statement
Research involving human participants the study was approved by Hyogo Prefectural Awaji Medical Center (receipt code 134, Date of approval: March 9, 2017).
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
13340_2021_529_MOESM1_ESM.pdf
Supplementary figure 1 Analysis by CGM. Analysis by CGM showed that the mean sensor glucose value was 123 mg/dL, the sensor glucose values varied widely, with lows below 70 mg/dL and highs above 180 mg/dL; Supplementary figure 2 Globin gene analysis. Globin gene analysis revealed no mutation in the β-globin and α1-globin genes but did detect a heterozygous mutation, GAG (glutamic acid) → AAG (lysine), at amino acid position 23 of the α2-globin gene, leading to the diagnosis of Hb Chad. (PDF 63 kb)
About this article
Cite this article
Yoshino, K., Hirota, Y., Ogawa, W. et al. A case of α-chain variant hemoglobin (Hb Chad) with falsely high HbA1c levels measured by immunoassay. Diabetol Int 13, 330–335 (2022). https://doi.org/10.1007/s13340-021-00529-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13340-021-00529-y